Why Xilinx Inc., Biogen Idec Inc., and Qualcomm Incorporated Are Today’s 3 Worst Stocks
John Divine, The Motley Fool - Motley Fool - Thu Apr 24, 7:04PM CDT
U.S. manufacturers are starting to hit their strides this spring, according to new data from the Census Bureau. Durable goods orders rose 2.6% in March from February, notably better than the 2% increase expected by Econoday; the strong demand is a...
Why Investors Should Love Biogen's Earnings Miss
Dan Carroll, The Motley Fool - Motley Fool - Thu Apr 24, 5:30PM CDT
Big biotech Biogen Idec has weathered the industry's storm in a rocky 2014. The stock's gained more than 9% despite the biotech sector's fall brought on by nervous investors concerned about the market's rally, and Biogen has plenty of room for...
Spectrum Pharma Candidate Gets Positive Data - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Apr 24, 4:50PM CDT
Spectrum Pharmaceuticals (SPPI) announced encouraging results from a phase II pivotal study on captisol-enabled melphalan.
Stock Market News for April 24, 2014 - Market News
Zacks Equity Research - Zacks Investment Research - Thu Apr 24, 9:06AM CDT
Benchmarks ended lower on Wednesday following disappointing corporate results and economic data
Earnings Roundup: Biogen's Tecfidera Wins More Share
Todd Campbell, The Motley Fool - Motley Fool - Thu Apr 24, 8:30AM CDT
Biogen remains a market leader in treating multiple sclerosis, an autoimmune disease that affects more than 1.1 million people in the U.S. and Europe. The company has launched a host of widely successful MS therapies over the past decade,...
Ambit Biosciences Slumps: AMBI Falls 7.1% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Apr 24, 7:49AM CDT
Ambit Biosciences saw a big move last session, as the company’s shares fell by over 7% on the day
Prothena Corporation plc (PRTA) Worth Watching: Stock Rises 9.5% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Apr 24, 7:44AM CDT
Prothena Corporation plc (PRTA) was a big mover last session, as the company saw its shares rally nearly 10.00% on the day.
Quintiles and Biogen Idec Announce Comprehensive Clinical Development Partnership
Business Wire - Thu Apr 24, 7:00AM CDT
Quintiles, the world's largest provider of biopharmaceutical development and commercial outsourcing services, and Biogen Idec (NASDAQ: BIIB) have entered into a five-year strategic clinical development agreement. The multi-year collaboration is designed to leverage the expertise and experience from both organizations to optimize Biogen Idec's clinical development processes.
Biogen EPS misses, guides up
at Investor's Business Daily - Wed Apr 23, 5:49PM CDT
The biotech's Q1 EPS jumped 25% to $2.47, but missed views by 9 cents. Revenue rose 50.5% to $2.13 bil, above views for $2 bil. U.S. sales of MS drug Tecfidera were $460 mil vs. views of $413 mil. Nearly all individual product sales beat consensus....
Biogen Q1, Guidance Strong
at Investor's Business Daily - Wed Apr 23, 5:46PM CDT
Big-cap biotech Biogen Idec reported solid Q1 revenue early Wednesday and guided 2014 above Wall Street's expectations, but the stock rose just a fraction as biotechs had a bad day and Biogen revealed it's being probed by authorities. Biogen (BIIB)...
Why Biogen (BIIB) Stock Is Down Today
at The Street - Wed Apr 23, 12:55PM CDT
Biogen (BIIB) shares fall as Biotech ETF as takes a hit in trading today
Biogen's Q1 Earnings Soar Y/Y on Tecfidera Sales - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Apr 23, 12:40PM CDT
Although Biogen (BIIB) missed earnings estimates, revenues surpassed expectations easily. The company also raised its guidance.
Interesting BIIB Put And Call Options For June 21st
at The Street - Wed Apr 23, 10:05AM CDT
Investors in Biogen Idec Inc saw new options begin trading this week, for the June 21st expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the BIIB options chain for the new June 21st contracts and identified one put...
Biogen Q1 Sales Beat Street, Guidance Strong
at Investor's Business Daily - Wed Apr 23, 9:11AM CDT
Big-cap biotech Biogen Idec (BIIB) reported solid Q1 revenue early Wednesday and guided 2014 above Wall Street's expectations, but the stock was down more than 1% in early trading in the stock market today. Biogen said revenue rose 50.5% over the...
Amgen's Q1 Earnings Decline Y/Y - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Apr 23, 8:40AM CDT
Amgen's first quarter results were disappointing with most of the products recording a sequential decline in sales.
Revance Therapeutics (RVNC) Soars: Stock Up 25.8% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Apr 23, 8:39AM CDT
Revance Therapeutics, Inc. was a big mover last session, as its shares rose nearly 26% on the day.
Alliance Fiber Optic, Talisman Energy, Gilead Sciences, Biogen Idec and Alexion Pharmaceuticals highlighted as Zacks Bull and Bear of the Day
PR Newswire - Wed Apr 23, 8:30AM CDT
Zacks Equity Research highlights Alliance Fiber Optic (Nasdaq:AFOP-Free Report) as the Bull of the Day and Talisman Energy (NYSE:TLM-Free Report) as the Bear of the Day. In addition, Zacks Equity Research provides analysis onGilead Sciences Inc. (Nasdaq:GILD-Free Report), Biogen Idec Inc. (Nasdaq:BIIB-Free Report) and Alexion Pharmaceuticals, Inc. (Nasdaq:ALXN-Free Report).
Why Biogen Idec (BIIB) Might Surprise This Earnings Season - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Apr 23, 7:43AM CDT
Biogen Idec (BIIB) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season. The company looks set to produce a positive earnings surprise and outperform analyst expectations.
Biogen Idec First Quarter 2014 Revenues Reach $2.1 Billion Driven by Continued Strength of MS Franchise
Business Wire - Wed Apr 23, 6:02AM CDT
--Neurology Pipeline Expands through Alzheimer's Disease Collaboration with Eisai
'Fast Money' Recap: Riding the Momentum
at The Street - Wed Apr 23, 4:00AM CDT
The trading panel looked at Amazon, Netflix and biotech stocks.